title: Heterogeneous effects of IL-2 on collagen-induced arthritis.
abstract: IL-2 is generally considered a pro-inflammatory cytokine that exacerbates Th1-mediated disease states, such as autoimmune arthritis. Consistent with this role for IL-2, recent studies from our laboratory demonstrate that IL-2 mRNA is markedly increased during the acute stage of collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis. To further define the role of IL-2 in CIA, the levels of IL-2 protein and its receptor and the effects of IL-2 administration were analyzed during CIA. IL-2 protein and IL-2R were preferentially expressed at disease onset, compared with later stages of disease. Administration of recombinant human IL-2 (rhIL-2) at, or just before, disease onset exacerbated disease; surprisingly, rhIL-2 given before disease onset inhibited CIA, associated with reduced cellular and humoral responses to type II collagen. Determination of in vivo serum levels of Th1 and Th2 cytokines in response to rhIL-2 treatment demonstrated that IFN-gamma, but not IL-4, was markedly up-regulated in response to IL-2. In mice treated with anti-IFN-gamma Ab, both early and late IL-2 administration exacerbated CIA. Thus, IL-2 can have two opposite effects on autoimmune arthritis, a direct stimulatory effect and an indirect suppressive effect that is mediated by IFN-gamma.
authors.affiliation: William S. Rowe Division of Rheumatology, Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
authors.forename: S
authors.initials: S
authors.lastname: Thornton
authors.forename: G P
authors.initials: GP
authors.lastname: Boivin
authors.forename: K N
authors.initials: KN
authors.lastname: Kim
authors.forename: F D
authors.initials: FD
authors.lastname: Finkelman
authors.forename: R
authors.initials: R
authors.lastname: Hirsch
mesh_terms: D000208:Acute Disease; D000818:Animals; D001169:Arthritis, Experimental / Q000209:etiology / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D001402:B-Lymphocytes / Q000276:immunology; D002417:Cattle; D002908:Chronic Disease; D003094:Collagen / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D018836:Inflammation Mediators / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000276:immunology / Q000502:physiology; D007376:Interleukin-2 / Q000008:administration & dosage / Q000096:biosynthesis / Q000276:immunology*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000008:administration & dosage; D013601:T-Lymphocytes / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism
chemical_list: D007106:Immune Sera; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma; D003094:Collagen